SELLAS Life Sciences Group, Inc. — 2021 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2021, filed March 31, 2022; it reports a full fiscal year, not a standalone fourth quarter. SELLAS is a clinical-stage biopharmaceutical company with no approved products. Its lead candidate, GPS, is being studied in Phase 3 for AML; NPS is a HER2-targeting candidate whose further development or partnering prospects have weakened.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| License revenue | $7.6 million | $1.9 million |
| Research and development expense | $15.7 million | $9.3 million |
| General and administrative expense | $11.3 million | $9.6 million |
| Operating loss | $25.3 million | $17.0 million |
| Net loss | $20.7 million | $16.8 million |
| Basic and diluted loss per share | $1.34 | $2.11 |
| Cash used in operating activities | $26.0 million | $10.4 million |
Revenue was licensing revenue under the 3D Medicines agreement, not product sales. SELLAS recognized the initial $9.5 million transaction price over the technology-transfer period, completed in 2021; it reported no royalty revenue. Traditional product margins are not applicable. The $5.7 million NPS impairment and $4.3 million gain from revaluing contingent consideration were noncash items.
At year-end, cash and cash equivalents were $21.4 million, total assets $26.3 million, total liabilities $5.9 million, and stockholders’ equity $20.3 million. The balance sheet lists no borrowings as a separate debt balance. The company stated that cash was insufficient for at least 12 months of planned operations from the financial-statement issuance date and disclosed substantial doubt about its ability to continue as a going concern. The auditor’s report included a going-concern emphasis. In 2021, SELLAS raised $9.0 million net through an at-the-market equity program and $3.1 million from warrant exercises.
Material changes versus 2020
- Net loss increased by $3.9 million. Higher R&D spending, the NPS impairment, and higher G&A outweighed increased license revenue and non-operating income.
- R&D expense rose $6.4 million, mainly from REGAL clinical-trial costs, GPS manufacturing and supply, and personnel.
- Operating cash use increased $15.6 million, while cash and cash equivalents declined from $35.3 million to $21.4 million.
- Year-end shares outstanding increased to 15.9 million from 14.3 million. Basic loss per share fell despite the larger net loss, reflecting a higher weighted-average share count.
Outlook, risks, contingencies, and unusual items
- Management expected REGAL to enroll approximately 116 patients, with enrollment projected for late 2022 or early Q1 2023 and the planned interim analysis after 80 deaths expected by the end of H1 2023, subject to event timing and assumptions. COVID-19-related site, staffing, supply, and enrollment delays remain risks.
- SELLAS expects continued losses and negative cash flows and says it needs substantial additional financing. Potential funding includes equity or debt, collaborations, and licensing; none is assured. Failure to raise funds could force delays, reductions, or termination of programs, a strategic transaction, or cessation of operations.
- In March 2022, China’s NMPA approved 3D Medicines’ GPS IND, triggering a $1.0 million milestone expected in Q2 2022. Further potential payments under the agreement total $192.5 million, plus royalties, but are contingent and not guaranteed.
- The $5.7 million impairment reduced NPS in-process R&D to zero after management concluded a breast-cancer license was unlikely and lowered its outlook for other indications. SELLAS said it was reassessing NPS options.
- Legacy Galena securities and derivative litigation settlements were covered by directors’ and officers’ insurance; final approval of the securities settlement was received February 24, 2022. Management reported effective disclosure controls and internal control over financial reporting; the auditor identified no critical audit matters.
Most important facts for investors to verify
- Whether SELLAS secures enough capital to fund operations beyond the disclosed runway, and the terms and dilution of any financing.
- Actual REGAL enrollment progress, interim-analysis timing, and whether the trial ultimately demonstrates clinically meaningful overall-survival benefit.
- Whether the expected $1.0 million China milestone was received and whether subsequent 3D Medicines development milestones are achieved.
- How management intends to pursue or monetize NPS following the impairment and unsuccessful breast-cancer licensing efforts.
- Reconcile reported cash burn with future clinical, manufacturing, and other commitments; confirm that contingent milestones and royalties are not assured cash inflows.